Literature DB >> 18982078

Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy.

Hector M Reyes1, Eric J Tingle, Andrew Z Fenves, Jennifer Spiegel, Elizabeth C Burton.   

Abstract

Mucormycosis (zygomycosis) is an acute and often fatal opportunistic fungal infection. Predisposing factors in the development of mucormycosis are nonspecific and include hyperglycemia, hematologic malignancies, neutropenia, pharmacologic immunosuppression, solid organ or bone marrow/stem cell transplantation, burns, trauma, malnutrition, and intravenous drug use. Mucormycosis has also been described in patients with iron and aluminum overload, patients on dialysis, and patients receiving iron chelating therapy. We describe a 75-year-old man with myelodysplastic syndrome and iron overload secondary to multiple red blood cell transfusions who had been treated with deferoxamine chelation therapy. He was admitted to the hospital for atrial fibrillation, developed multiple organ failure, and died. Pulmonary invasive mucormycosis was demonstrated at autopsy. This case further documents an association between invasive mucormycosis, iron overload, and deferoxamine therapy.

Entities:  

Year:  2008        PMID: 18982078      PMCID: PMC2566908          DOI: 10.1080/08998280.2008.11928431

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  11 in total

1.  Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis.

Authors:  J Maertens; H Demuynck; E K Verbeken; P Zachée; G E Verhoef; P Vandenberghe; M A Boogaerts
Journal:  Bone Marrow Transplant       Date:  1999-08       Impact factor: 5.483

Review 2.  Mucormycosis: association with deferoxamine therapy.

Authors:  A L Daly; L A Velazquez; S F Bradley; C A Kauffman
Journal:  Am J Med       Date:  1989-10       Impact factor: 4.965

3.  Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).

Authors:  J Van Cutsem; J R Boelaert
Journal:  Kidney Int       Date:  1989-12       Impact factor: 10.612

4.  Effects of iron and desferrioxamine on Rhizopus infection.

Authors:  F Abe; H Inaba; T Katoh; M Hotchi
Journal:  Mycopathologia       Date:  1990-05       Impact factor: 2.574

5.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.

Authors:  J R Boelaert; J Van Cutsem; M de Locht; Y J Schneider; R R Crichton
Journal:  Kidney Int       Date:  1994-03       Impact factor: 10.612

7.  Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.

Authors:  G A Verpooten; P C D'Haese; J R Boelaert; I Becaus; L V Lamberts; M E De Broe
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

Review 8.  Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment.

Authors:  R M Prabhu; R Patel
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

Review 9.  Mucormycosis.

Authors: 
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

Review 10.  Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry.

Authors:  J R Boelaert; A Z Fenves; J W Coburn
Journal:  Am J Kidney Dis       Date:  1991-12       Impact factor: 8.860

View more
  3 in total

Review 1.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  Antibacterial activities of iron chelators against common nosocomial pathogens.

Authors:  Mitchell G Thompson; Brendan W Corey; Yuanzheng Si; David W Craft; Daniel V Zurawski
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

3.  Mucormycosis following COVID-19 infection-An epidemic developing in a pandemic, a case series from a tertiary care hospital of India.

Authors:  Abhishek Singhai; Sooraj Unnikrishnan; Pragya Jain
Journal:  J Family Med Prim Care       Date:  2022-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.